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A bs tr ac t
Background
Atherosclerotic intracranial arterial stenosis is an important cause of stroke that is 
increasingly being treated with percutaneous transluminal angioplasty and stenting 
(PTAS) to prevent recurrent stroke. However, PTAS has not been compared with medi-
cal management in a randomized trial.
Methods
We randomly assigned patients who had a recent transient ischemic attack or stroke 
attributed to stenosis of 70 to 99% of the diameter of a major intracranial artery to 
aggressive medical management alone or aggressive medical management plus PTAS 
with the use of the Wingspan stent system. The primary end point was stroke or 
death within 30 days after enrollment or after a revascularization procedure for the 
qualifying lesion during the follow-up period or stroke in the territory of the quali-
fying artery beyond 30 days.
Results
Enrollment was stopped after 451 patients underwent randomization, because the 
30-day rate of stroke or death was 14.7% in the PTAS group (nonfatal stroke, 12.5%; 
fatal stroke, 2.2%) and 5.8% in the medical-management group (nonfatal stroke, 5.3%; 
non–stroke-related death, 0.4%) (P = 0.002). Beyond 30 days, stroke in the same ter-
ritory occurred in 13 patients in each group. Currently, the mean duration of follow-
up, which is ongoing, is 11.9 months. The probability of the occurrence of a primary 
end-point event over time differed significantly between the two treatment groups 
(P = 0.009), with 1-year rates of the primary end point of 20.0% in the PTAS group 
and 12.2% in the medical-management group.
Conclusions
In patients with intracranial arterial stenosis, aggressive medical management was 
superior to PTAS with the use of the Wingspan stent system, both because the risk 
of early stroke after PTAS was high and because the risk of stroke with aggressive 
medical therapy alone was lower than expected. (Funded by the National Institute of 
Neurological Disorders and Stroke and others; SAMMPRIS ClinicalTrials.gov num-
ber, NCT00576693.)
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Atherosclerotic intracranial ar-terial stenosis is one of the most common causes of stroke worldwide1-6 and is as-
sociated with a high risk of recurrent stroke.7-9 
Patients with a recent transient ischemic attack 
(TIA) or stroke and severe stenosis (70 to 99% of 
the diameter of a major intracranial artery) are at 
particularly high risk for recurrent stroke in the 
territory of the stenotic artery (approximately 23% 
at 1 year) despite treatment with aspirin and stan-
dard management of vascular risk factors.8,10 
Therefore, alternative therapies are urgently need-
ed for these patients.
Two strategies have emerged for the treatment 
of high-risk patients: aggressive medical therapy 
(combination antiplatelet therapy and intensive 
management of risk factors) and percutaneous 
transluminal angioplasty and stenting (PTAS). 
Over the past decade, intracranial PTAS has in-
creasingly been used in clinical practice in the 
United States and other countries.11-19 Currently, 
the self-expanding Wingspan stent (Boston Scien-
tific) is the only device approved by the Food and 
Drug Administration (FDA) for use in patients 
with atherosclerotic intracranial arterial stenosis; 
it has been available since 2005 for the treatment 
of patients with 50 to 99% stenosis who have had 
a TIA or stroke while receiving antithrombotic 
therapy.20
Because of uncertainty regarding the safety and 
efficacy of aggressive medical management alone 
as compared with aggressive medical management 
plus PTAS with the use of the Wingspan stent 
system, we began a randomized trial in Novem-
ber 2008 to compare these two treatments in high-
risk patients with intracranial arterial stenosis. 
On April 5, 2011, the trial’s independent data and 
safety monitoring board recommended that en-
rollment be stopped because of safety concerns 
regarding the risk of periprocedural stroke or 
death in the PTAS group and because futility 
analyses indicated that there was virtually no 
chance that a benefit from PTAS would be shown 
by the end of the follow-up period if enrollment 
continued. Although follow-up of patients is on-
going, the clinical importance of these findings 
mandated the reporting of the current results.
Me thods
Study Design and Oversight
Details of the trial design have been published pre-
viously.21 This study is an investigator-initiated, 
randomized, clinical trial funded by the National 
Institute of Neurological Disorders and Stroke and 
conducted at 50 sites in the United States. Stryker 
Neurovascular (formerly Boston Scientific Neuro-
vascular) provided the study devices and supple-
mental funding for third-party distribution of de-
vices and continues to provide funding for site 
monitoring and auditing of the study. The Investi-
gator-Sponsored Study Program of AstraZeneca 
donates rosuvastatin (Crestor) to study patients. 
Other industry partners are listed at the end of the 
article. None of the industry partners participated 
in the design of the trial or in the analysis or re-
porting of the results. The study protocol, available 
with the full text of this article at NEJM.org, was 
approved by the institutional review board at each 
site, and the FDA issued an investigational device 
exemption to enable us to carry out the study.
The data and safety monitoring board met 
every 6 months and reviewed monthly reports to 
monitor the study’s progress and the accumulated 
data. Two interim efficacy analyses were planned 
when approximately 33% and 66% of the required 
primary end points had occurred. There were no 
prespecified stopping rules for safety.
Study Patients
Eligible patients had a TIA or nondisabling stroke 
within 30 days before enrollment, attributed to 
angiographically verified stenosis of 70 to 99% of 
the diameter of a major intracranial artery. The 
other eligibility criteria are provided in the study 
protocol. All the patients gave written informed 
consent to participate, and patients who did not 
undergo diagnostic angiography as part of rou-
tine care gave consent for angiography as part of 
the study protocol.
Treatments
Aggressive Medical Management
The rationale for the medical-management regi-
men and details on the management of risk fac-
tors in the study patients have been published pre-
viously.21-23 Medical management is identical in 
the two groups and consists of aspirin, at a dose 
of 325 mg per day; clopidogrel, at a dose of 75 mg 
per day for 90 days after enrollment; management 
of the primary risk factors (elevated systolic blood 
pressure and elevated low-density lipoprotein [LDL] 
cholesterol levels); and management of secondary 
risk factors (diabetes, elevated non–high-density 
lipoprotein [non-HDL] cholesterol levels, smoking, 
excess weight, and insufficient exercise) with the 
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help of a lifestyle modification program. With re-
spect to the primary risk factors, we targeted a 
systolic blood pressure of less than 140 mm Hg 
(<130 mm Hg in the case of patients with diabetes) 
and an LDL cholesterol level of less than 70 mg 
per deciliter (1.81 mmol per liter). We provide the 
aspirin, clopidogrel, one drug from each major 
class of antihypertensive agents, rosuvastatin, and 
the lifestyle program to the study patients.
PTAS Procedure
PTAS was performed by neurointerventionists who 
were selected by a committee of experienced neu-
rointerventionists on the basis of their review of 
procedure notes and outcomes for the 20 most re-
cent consecutive cases of intracranial stenting or 
angioplasty (if angioplasty had been performed 
to treat atherosclerosis) performed by the neuro-
interventionists under consideration. Further de-
tails regarding the credentialing process and the 
monitoring of the interventionists’ performance 
of PTAS during the trial have been published pre-
viously.21 Patients who were randomly assigned 
to PTAS were required to undergo the procedure 
within 3 business days after randomization. Pa-
tients who were not taking clopidogrel at a dose 
of 75 mg each day for at least 5 days before PTAS 
were given a 600-mg loading dose of clopidogrel 
between 6 and 24 hours before PTAS. Details of 
the procedure, which was performed under gen-
eral anesthesia with the use of the Gateway PTA 
Balloon Catheter and Wingspan Stent System (both 
manufactured by Boston Scientific Corporation), 
and of the care of the patients after the procedure 
are provided in the protocol.
Follow-up and Assessment of Outcome
Patients were evaluated at the time of study entry, 
at 4 days, and at 30 days and have continued to be 
evaluated every 4 months; patients undergo as-
sessments until 90 days after a primary end point 
occurs, the patient dies, 3 years of follow-up have 
been completed, or the close-out visit for the trial 
is held, which will occur when the last patient 
enrolled has been followed for 1 year. At follow-
up visits, patients are examined by study neurolo-
gists who also manage the patients’ vascular risk 
factors. If a stroke is suspected during the follow-up 
period, the patient is examined by the study neu-
rologist, and magnetic resonance imaging (MRI) 
or computed tomography (CT) of the brain is typi-
cally performed. Because the treatment assign-
ment is known to the study neurologist, we require 
that a second site neurologist, who is not aware of 
the treatment assignments, evaluate any patient 
who has had a prolonged TIA (lasting more than 
1 hour) or mild ischemic stroke (an increase in 
the patient’s score on the National Institutes of 
Health Stroke Scale [NIHSS] of <4 points from the 
score at study entry), since these events may be 
difficult to classify. (The NIHSS is a 42-point scale 
that quantifies neurologic deficits in 11 cate-
gories, with higher scores indicating more severe 
deficits.) The assessments of both neurologists are 
sent for central adjudication.
All the end points are adjudicated by indepen-
dent panels of neurologists and cardiologists who 
are not informed of the treatment assignments. 
The primary end point is stroke or death within 
30 days after enrollment or after a revasculariza-
tion procedure for the qualifying lesion during 
the follow-up period (i.e., angioplasty for symp-
tomatic restenosis in a patient in the PTAS group 
or placement of a stent in a patient in the medical-
management group) or ischemic stroke in the ter-
ritory of the qualifying artery between day 31 and 
the end of the follow-up period. Ischemic stroke 
is defined as a new focal neurologic deficit of 
sudden onset, lasting at least 24 hours, that is not 
associated with a hemorrhage on CT or MRI of the 
brain. Ischemic strokes are further classified by 
the neurologic adjudicators as being either in the 
territory or out of the territory of the qualifying 
artery. Symptomatic brain hemorrhage is defined 
as a parenchymal, subarachnoid, or intraventric-
ular hemorrhage detected on CT or MRI that is 
associated with a seizure or with new neurologic 
signs or symptoms lasting at least 24 hours; it is 
included as a primary end point only if it occurs 
within 30 days after enrollment or within 30 days 
after a revascularization procedure for the quali-
fying lesion during the follow-up period.
Statistical Analysis
The mean length of follow-up was designed to be 
2 years. In the Warfarin–Aspirin Symptomatic In-
tracranial Disease trial (WASID; ClinicalTrials.gov 
number, NCT00004728),7 the rate of the same pri-
mary end point among patients with symptoms 
within 30 days before enrollment and 70 to 99% 
stenosis was 29% at 2 years. With adjustment of 
that rate to account for an estimated 15% relative 
reduction in risk with aggressive medical manage-
ment, the projected rate of the primary end point 
in the medical-management group was 24.7% at 
2 years. We estimated that we would need to en-
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roll 382 patients in each group for the study to 
have 80% power to show a relative reduction of 
35% with PTAS in the risk of the primary end 
point, assuming a 5% crossover rate from the 
medical-management group to the PTAS group 
and a 2% loss to follow-up, with the use of a two-
sided log-rank test, at a type I error rate of 0.05.
We tested the primary hypothesis by compar-
ing the rate of the primary end point between the 
two treatment groups using a two-sided log-rank 
test. Data from patients who were lost to follow-
up or who withdrew consent were censored at the 
last contact date. Secondary end points were ana-
lyzed with the use of the same techniques. The 
probability of a primary end point by 30 days after 
enrollment was compared between the two treat-
ment groups with the use of a z test. All analyses 
were performed in the intention-to-treat popu-
lation unless otherwise specified. All reported 
P values are two-sided and have not been adjusted 
for multiple testing.
R esult s
Patients
Of the 451 patients who underwent randomiza-
tion, 227 were assigned to the medical-manage-
ment group and 224 to the PTAS group (see the 
figure in the Supplementary Appendix, available 
at NEJM.org). There were no significant differences 
between the two groups with respect to any of the 
baseline characteristics of the patients (Table 1), 
but the groups did differ significantly at various 
times during the trial with respect to some of the 
measures of risk factors (Table 2, and expanded 
version of Table 2 in the Supplementary Appen-
dix). Of the 224 patients in the PTAS group, 16 
(7.1%) did not have a stent placed (the procedure 
was not performed in 4 patients, the procedure was 
aborted before the lesion was accessed in 7, and 
angioplasty alone was performed in 5). Of the 
227 patients in the medical-management group, 
9 (4.0%) underwent PTAS after a TIA during the 
follow-up period.
End Points
The data on end points presented below are based 
on all adverse events as of April 28, 2011, when 
the last patient enrolled completed the 30-day eval-
uation. Data from patients without events who 
had follow-up visits after that date were censored 
as of April 28, 2011, for all analyses.
Primary End Points within 30 Days after Enrollment
The probability of the primary end point was 14.7% 
(involving 33 patients) in the PTAS group and 5.8% 
(involving 13 patients) in the medical-management 
group (P = 0.002) (Fig. 1 and Table 3). There were 
five stroke-related deaths in the PTAS group (2.2%) 
and one non–stroke-related death in the medical-
management group (0.4%). A total of 10 of the 33 
strokes in the PTAS group (30.3%) and none of the 
12 in the medical-management group were symp-
tomatic brain hemorrhages (P = 0.04 by Fisher’s 
exact test). Further details of the types of strokes 
that occurred in the two groups are provided in 
Table 3.
Of the 33 strokes in the PTAS group that 
occurred within 30 days after enrollment, 25 oc-
curred within 1 day after the procedure and 8 oc-
curred 2 to 6 days later. The 33 strokes occurred 
at 25 investigational sites. Of 6 sites at which more 
than 1 periprocedural stroke occurred, 5 were 
among the highest-enrolling sites. The 30-day rate 
of stroke among patients who underwent PTAS 
was 13.5% at the highest-enrolling sites (i.e., at 12 
sites that enrolled half the patients) and 14.7% 
at the other sites (38 sites that enrolled the other 
half) (P = 0.77). The risk of periprocedural stroke 
did not diminish over the course of the enroll-
ment period (P = 0.20 by the Cochran–Armitage 
test for trend).
Primary End Points beyond 30 Days
Beyond 30 days, nonfatal ischemic strokes in the 
territory of the qualifying artery have occurred in 
13 patients in each group (Table 3). The probabil-
ity of the occurrence of a primary end point over 
the entire follow-up period after enrollment dif-
fered significantly between the two treatment 
groups (P = 0.009), with 1-year rates of the primary 
end point of 20.0% in the PTAS group and 12.2% 
in the medical-management group (Fig. 1 and 
Table 3). An as-treated analysis that excluded 11 
patients in the PTAS group who did not undergo 
angioplasty or have a stent placed (3 of whom had 
a stroke) and 9 patients in the medical-manage-
ment group who underwent PTAS during the fol-
low-up period (3 of whom had a stroke after PTAS) 
showed the same result (P = 0.009).
Secondary End Points and Other Adverse Events
Table 3 shows the secondary end points and other 
major adverse events during the follow-up period 
in each group. The rates of any stroke and of any 
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Table 1. Baseline Characteristics of the Patients.*
Characteristic
Medical-Management 
Group
(N = 227)
PTAS Group 
(N = 224)
Age — yr 59.5±11.8 61.0±10.7
Male sex — no. (%) 145 (63.9) 127 (56.7)
Race — no. (%)†
Black 50 (22.0) 55 (24.6)
White 161 (70.9) 160 (71.4)
Other 16 (7.0) 9 (4.0)
Hypertension — no. (%) 203 (89.4) 201 (89.7)
Diabetes — no. (%) 103 (45.4) 106 (47.3)
Lipid disorder — no. (%) 203 (89.4) 194 (86.6)
Smoking history — no./total no. (%)
Never 78/227 (34.4) 90/223 (40.4)
Former 80/227 (35.2) 79/223 (35.4)
Current 69/227 (30.4) 54/223 (24.2)
History of coronary artery disease — no. (%) 59 (26.0) 47 (21.0)
History of stroke other than qualifying event — no. (%) 58 (25.6) 60 (26.8)
Qualifying event — no. (%)
Stroke 152 (67.0) 142 (63.4)
TIA 75 (33.0) 82 (36.6)
Already receiving antithrombotic therapy at time of qualifying event — 
no. (%)
141 (62.1) 145 (64.7)
Time from qualifying event to randomization — days
Median 7 7
Interquartile range 4–19 4–16
Symptomatic qualifying artery — no. (%)
Internal carotid 49 (21.6) 45 (20.1)
Middle cerebral 105 (46.3) 92 (41.1)
Vertebral 22 (9.7) 38 (17.0)
Basilar 51 (22.5) 49 (21.9)
Stenosis of symptomatic qualifying artery‡
Mean percentage stenosis 81±7 80±7
Distribution — no./total no. (%)
70–79% stenosis 102/227 (44.9) 107/223 (48.0)
80–89% stenosis 97/227 (42.7) 92/223 (41.3)
90–99% stenosis 28/227 (12.3) 24/223 (10.8)
* Plus–minus values are means ±SD. Baseline characteristics of the two groups were compared with the use of either an 
independent groups t-test (for means) or a chi-square test (for percentages). None of the characteristics differed sig-
nificantly between the groups (P>0.05 for all comparisons). PTAS denotes percutaneous transluminal angioplasty and 
stenting.
† Race was self-reported.
‡ Stenosis was quantified on the basis of a reading of the angiogram by the site interventionist.
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major hemorrhage were significantly higher in 
the PTAS group than in the medical-management 
group. The difference between the two groups in 
the rate of death or any stroke (16.3% vs. 23.2%) 
was not significant (P = 0.06).
Discussion
Contrary to what we hypothesized, the results of 
this trial showed that aggressive medical therapy 
was superior to PTAS with the use of the Wing-
Table 2. Measures of Risk Factors at Baseline and 4 Months.*
Variable
Medical-Management 
Group
(N = 227)
PTAS Group
(N = 224)
Baseline 4 Mo Baseline 4 Mo
Clinical factor
Blood pressure
No. of patients evaluated 227 179 220 173
Systolic — mm Hg 146.8±21.8 134.8±17.0 143.9±20.6 133.1±15.9
Diastolic — mm Hg† 82.3±12.0 77.3±10.0 77.9±10.7 76.2±9.7
Lipids‡
No. of patients evaluated 226 175 219 174
LDL cholesterol — mg/dl 97.7±36.6 72.8±26.0 96.3±38.5 75.9±40.9
HDL cholesterol — mg/dl 38.8±10.1 41.9±11.4 37.8±10.6 43.2±13.3
Non-HDL cholesterol — mg/dl 116.6±40.3 90.9±30.8 116.6±43.9 94.3±50.2
Glycated hemoglobin in patients with diabetes§
No. of patients evaluated 98 47 102 50
Level of glycated hemoglobin — % 8.3±2.3 7.5±2.0 7.9±2.1 7.8±2.4
Body-mass index¶
No. of patients evaluated 227 180 224 170
Value 30.7±6.3 30.4±6.4 30.3±6.2 30.0±6.2
Lifestyle factor
No. of patients evaluated 227 181 223 173
Current smoker — % 30.4 20.4 24.2 17.3
Moderate or vigorous exercise — %‖ 29.1 56.6 34.2 56.1
* Plus–minus values are means ±SD. Risk-factor measures in both groups at 30 days and at 1 year are provided in Table 2 
in the Supplementary Appendix. To convert the values for cholesterol to millimoles per liter, multiply by 0.02586. PTAS 
denotes percutaneous transluminal angioplasty and stenting.
† The difference in diastolic blood pressure at baseline between the two groups is significant (P<0.001).
‡ Lipid levels at baseline and 4 months were measured at the Central Lipid Laboratory, with low-density lipoprotein (LDL) 
cholesterol levels measured directly. Non-high-density lipoprotein (non-HDL) cholesterol is total cholesterol minus 
HDL cholesterol, or the sum of LDL cholesterol and very-low-density lipoprotein cholesterol.
§ Levels shown are baseline and 6-month levels, rather than baseline and 4-month levels (the protocol did not require 
levels to be measured at 4 months). Diabetes was defined according to the 2010 criteria of the American Diabetes 
Association.
¶ The body-mass index is the weight in kilograms divided by the square of the height in meters.
‖ Moderate or vigorous exercise was defined as a score on the Physician-based Assessment and Counseling for Exercise 
(PACE) evaluation of 4 to 8, with 4 indicating vigorous exercise less than three times per week or moderate exercise 
less than five times per week and 8 indicating vigorous exercise at least 3 days a week for at least the previous 6 months. 
Examples of moderate exercise include brisk walking, gardening, and slow cycling for at least 10 minutes; examples of 
vigorous exercise include jogging, running, and fast cycling for at least 20 minutes. A total of 182 patients were included 
in the medical-management group at 4 months.
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span system in high-risk patients with intracra-
nial stenosis, because the rate of periprocedural 
stroke after PTAS was higher than expected and 
the rate of stroke in the medical-management 
group was lower than estimated. The 30-day rate 
of stroke or death in the PTAS group (14.7%) is 
substantially higher than the rates previously re-
ported with the use of the Wingspan stent in the 
phase I trial and in two registries (rates ranging 
from 4.4% to 9.6%).10,20,25 The higher rate in the 
current study does not reflect inexperience of the 
operators, because most of the interventionists 
who participated in the registries also participat-
ed in this trial, and all the interventionists in this 
trial were credentialed to participate on the basis of 
evidence of their experience. In addition, the rates 
of periprocedural stroke did not decline over the 
course of the enrollment period and did not dif-
fer significantly between high-enrolling sites and 
low-enrolling sites in this trial.
One possible explanation for the higher rate of 
periprocedural stroke in this trial as compared with 
the registries is that all the patients in this study 
had stenosis of 70 to 99% and recent symptoms, 
whereas the registries included patients with steno-
sis of 50 to 99% and symptoms that had occurred 
more than 30 days before enrollment. Recent 
symptoms may be a marker for unstable plaque, 
which could increase the risk of distal embolism 
during stenting, as has been reported with extra-
cranial carotid stenting.26,27 Another explanation 
for the higher rate of periprocedural stroke in this 
trial is that the rigorous protocol for evaluating 
events (i.e., evaluation of all potential end points 
by neurologists, the adjudication process, and site-
monitoring visits) could have resulted in the de-
tection of some milder strokes that may not have 
been detected in the registries. However, the per-
centage of primary end-point strokes in the PTAS 
group that were disabling or fatal (35%; 16 of 46 
patients) is higher than the percentage of primary 
end-point strokes that were categorized as major 
in the stenting group (21%) or the endarterectomy 
group (28%) in a recent randomized trial involv-
ing patients with extracranial carotid stenosis.28
The rate of stroke in the medical-management 
group was much lower than expected. Patients in 
the WASID trial with the same entry criteria who 
were treated with aspirin or warfarin and standard 
management of risk factors had a 30-day rate of 
stroke or death of 10.7% and a 1-year rate of the 
primary end point of 25%.10 In contrast, the cor-
responding rates in the medical-management 
group in this trial were 5.8% and 12.2%. Although 
we expected the rate of stroke to be reduced with 
intensive management of risk factors — on the 
basis of post hoc analyses from the WASID trial 
that suggested that lowering LDL cholesterol and 
systolic blood pressure could reduce the risk of 
stroke22,29 — we were surprised at the extent and 
rapidity of the reduction. It is also possible that 
the combination of aspirin and clopidogrel played 
an important role in lowering the early risk of 
stroke. This is supported by the results of a study 
of transcranial Doppler ultrasonography involving 
patients with recently symptomatic intracranial 
stenosis, which showed that aspirin and clopido-
grel, as compared with aspirin alone, reduced the 
frequency of ipsilateral distal microemboli.30 The 
effect of the lifestyle modification program on 
the outcome can be determined only at the end 
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of the follow-up period, but it is unlikely that it 
contributed to a reduction in the risk of stroke in 
the medical-management group within 30 days 
after enrollment.
The difference between the treatment groups 
in the rate of the primary end point is driven by 
the early events, since the rates of the primary end 
point beyond 30 days are currently similar in the 
two groups. However, fewer than half the pa-
tients have been followed for longer than 1 year. 
Therefore, continued follow-up of the patients who 
are currently enrolled will be important to deter-
mine the long-term outcome in the two groups. 
Among patients who are receiving medical man-
agement only, progression of stenosis may occur 
over time that could result in a stroke from a distal 
embolism or hypoperfusion.31-35 Among patients 
in whom a stent has been placed, restenosis occurs 
in 25 to 30% within 6 months after intracranial 
PTAS36,37 and could also lead to later stroke.
Patients with symptoms that occurred more 
than 30 days before enrollment or with stenosis 
of 50 to 69% of an intracranial artery were ex-
cluded from this trial because their risk of stroke 
while receiving standard medical care is relatively 
low (approximately 3 to 9% at 1 year 8,21), making 
it unlikely that they would benefit from PTAS. 
These patients could have an even lower risk of 
stroke if they received aggressive medical therapy. 
This trial did not evaluate angioplasty alone or 
other devices (e.g., balloon-mounted stents) that 
are used off-label to treat patients with intracra-
nial stenosis. Although these devices may have 
benefits over the Wingspan system (e.g., single-
step delivery and deployment of the stent and less 
residual stenosis after the procedure), none have 
been compared with medical management.
The current results of this trial indicate that 
medical therapy as delivered in this trial is superior 
to PTAS with the Wingspan stent system, which 
is associated with a high risk of periprocedural 
stroke or death in this population. Although not 
all the components of the aggressive medical 
regimen used in this trial may be easy to dupli-
cate in clinical practice, essential elements can 
readily be adopted, including adding clopidogrel 
to aspirin for the first 90 days and following the 
trial’s protocol with respect to lowering blood 
pressure and LDL cholesterol in order to achieve 
target levels that are based on national guide-
lines.38,39
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